Clinical Trials in Overland Park Kansas

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Placebo Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
NCT04040816
Conditions: Gout; Hyperuricemia
Intervention: Drug: SAP-001
Sponsor: Shanton Pharma Co., Ltd.
Recruiting
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Observation; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT03709082
Conditions: HER2-positive Breast Cancer; Breast Cancer Metastatic
Interventions: Drug: Palbociclib 75mg; Drug: Letrozole 2.5mg; Drug: T-DM1; Drug: Palbociclib 100mg; Drug: Palbociclib 125mg; Drug: Palbociclib
Sponsors: University of Kansas Medical Center; Pfizer
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Condition: Lumbar Spinal Stenosis
Intervention: Device: MILD
Sponsor: Vertos Medical, Inc.
Recruiting
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
NCT03304639
Conditions: Stage III Merkel Cell Carcinoma AJCC v7; Stage IIIA Merkel Cell Carcinoma AJCC v7; Stage IIIB Merkel Cell Carcinoma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Biological: Pembrolizumab; Radiation: Stereotactic Body Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
NCT03244384
Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Resectable Lung Non-Small Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
NCT03698019
Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03414970
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma
Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954874
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
NCT02775851
Condition: Desmoplastic Melanoma
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT02761057
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: Metastatic Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
NCT02004275
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc.
Recruiting
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
NCT02972840
Condition: Lymphoma, Mantle Cell
Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab; Drug: Placebo in combination with bendamustine and rituximab
Sponsor: Acerta Pharma BV
Recruiting
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT03238495
Condition: HER2-positive Breast Cancer
Interventions: Drug: Taxotere, Carboplatin, Herceptin + Pertuzumab; Drug: Metformin
Sponsor: Qamar Khan
Recruiting
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03845296
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Intervention: Drug: Rucaparib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Collecting Orthopedic Safety and Performance Data Using Surgeons Clinical Outcomes Registry (SCOR)
NCT04032444
Condition: Orthopedics
Intervention:
Sponsor: Tornier, Inc.
Recruiting
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
NCT03971071
Condition: Migraine Headache
Interventions: Drug: Erenumab 70 mg; Drug: Erenumab 140mg; Drug: Placebo
Sponsor: Amgen
Recruiting
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT02393794
Conditions: Triple-Negative Breast Cancer; Breast Cancer
Interventions: Drug: Romidepsin; Drug: Cisplatin; Drug: Nivolumab
Sponsors: Priyanka Sharma; Celgene Corporation; Bristol-Myers Squibb
Recruiting
CLUSTER Trial for Outbreak Detection and Response
NCT04053075
Condition: Cluster Detection
Interventions: Other: Routine cluster detection; Other: Enhanced cluster detection
Sponsors: Harvard Pilgrim Health Care; Hospital Corporation of America (HCA) Healthcare; Brigham and Women's Hospital; University of California, Irvine; Harvard School of Public Health; Rush University; Duke University; University of Massachusetts, Amherst; University of California, San Francisco; Cook County Health & Hospitals System; Centers for Disease Control and Prevention
Recruiting
Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
NCT03609021
Conditions: Breast Carcinoma; Estrogen Receptor Negative; Progesterone Receptor Negative
Interventions: Procedure: Screening Mammography; Procedure: Biospecimen Collection
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Algovita Spinal Cord Stimulation System Hi-Fi Study
NCT03622866
Condition: Chronic Pain
Interventions: Device: Ultra-high pulse width stimulation; Device: Traditional pulse width stimulation
Sponsors: Nuvectra; Bright Research Partners
Recruiting
Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03147287
Condition: Metastatic Breast Cancer
Interventions: Drug: Palbociclib; Drug: Fulvestrant; Drug: Avelumab
Sponsors: Dana-Farber Cancer Institute; Pfizer
Recruiting
A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
NCT03633396
Condition: Palmoplantar Pustulosis
Interventions: Biological: ANB019; Drug: Placebo
Sponsor: AnaptysBio, Inc.
Recruiting
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
NCT04015518
Condition: Palmoplantar Pustulosis (PPP)
Interventions: Drug: Spesolimab; Drug: Placebo
Sponsor: Boehringer Ingelheim
Recruiting
Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
NCT03996265
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Cancer Fatigue; Cancer Survivor; Complete Remission; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Bupropion Hydrochloride Controlled-release; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Gary Morrow; National Cancer Institute (NCI)
Recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
NCT03983980
Condition: Plaque Psoriasis
Interventions: Drug: Tapinarof (DMVT-505); Drug: Vehicle Cream
Sponsors: Dermavant Sciences GmbH; IQVIA Biotech
Recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585
Conditions: Basaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Image Guided Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
NCT03933215
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine Tablets
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
NCT03933202
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine Tablets
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
Condition: Psoriasis
Interventions: Drug: PF-06826647 or Placebo; Drug: PF-06826647
Sponsor: Pfizer
Recruiting
Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors
NCT03887702
Conditions: Hepatitis B Virus Positive; Malignant Solid Neoplasm
Interventions: Other: Best Practice; Other: Laboratory Biomarker Analysis; Drug: Tenofovir Alafenamide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema
NCT03866473
Condition: Diabetic Macular Edema
Interventions: Device: Retilux; Device: Sham Light Device
Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; PhotoOptx LLC
Recruiting
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
NCT03825315
Condition: Plantar Fasciitis
Interventions: Biological: DAXI for Injection: LOW Dose; Other: DAXI for Injection: HIGH Dose; Other: Placebo
Sponsor: Revance Therapeutics, Inc.
Recruiting
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
NCT03821402
Condition: Upper Limb Spasticity
Interventions: Biological: DAXI for injection dose LOW DOSE; Biological: DAXI for injection dose MEDIUM DOSE; Biological: DAXI for injection Dose HIGH DOSE; Other: Placebo
Sponsor: Revance Therapeutics, Inc.
Recruiting
A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
NCT03816163
Conditions: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: zolbetuximab; Drug: nab-paclitaxel; Drug: gemcitabine
Sponsor: Astellas Pharma Global Development, Inc.
Recruiting
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
NCT03811002
Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Atezolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
NCT03809663
Condition: Atopic Dermatitis
Interventions: Drug: Tezepelumab; Other: Placebo
Sponsors: Amgen; AstraZeneca
Recruiting
Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer
NCT03801902
Conditions: Lung Non-Small Cell Carcinoma; PD-L1 Overexpression; Recurrent Lung Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Biological: Durvalumab; Radiation: Fractionated Stereotactic Radiation Therapy; Radiation: Hypofractionated Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT03793179
Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8
Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed
Sponsor: National Cancer Institute (NCI)
Recruiting
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Malignant Neoplasm in the Viscera; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Cabozantinib; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
The SNAP Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Neuropathic Post-Amputation Pain
NCT03783689
Conditions: Neuropathic Pain; Amputation
Intervention: Device: SPRINT Peripheral Nerve Stimulation (PNS) System
Sponsor: SPR Therapeutics, Inc.
Recruiting
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
NCT03778931
Condition: Breast Cancer
Interventions: Drug: Elacestrant; Drug: Standard of Care
Sponsor: Radius Pharmaceuticals, Inc.
Recruiting
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
NCT03777436
Condition: Psoriasis
Interventions: Drug: Apremilast; Other: Placebo
Sponsor: Celgene
Recruiting
To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
NCT03777059
Condition: Episodic Migraine
Interventions: Drug: Atogepant 30 mg; Drug: Atogepant 60 mg; Drug: Placebo; Drug: Atogepant 10 mg
Sponsor: Allergan
Recruiting
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
NCT03757949
Condition: Bladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Dietary Supplement: Nutritional Intervention; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03738423
Condition: Atopic Dermatitis
Interventions: Drug: REGN3500; Drug: REGN3500-Matching Placebo
Sponsors: Regeneron Pharmaceuticals; Sanofi
Recruiting
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29
Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
NCT03712605
Conditions: Pathologic Stage I Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions: Other: Best Practice; Biological: Pembrolizumab; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
NCT03701282
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
NCT03683030
Condition: Atrial Fibrillation
Intervention: Device: Radiofrequency Ablation
Sponsor: Biosense Webster, Inc.
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Conditions: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Interventions: Drug: Abiraterone; Drug: Bicalutamide; Drug: Degarelix; Drug: Docetaxel; Drug: Flutamide; Drug: Goserelin Acetate; Drug: Histrelin Acetate; Drug: Leuprolide Acetate; Drug: Nilutamide; Procedure: Orchiectomy; Drug: Prednisone; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Procedure: Radical Prostatectomy; Drug: Triptorelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Effects of Pneumatic Vitreolysis on Macular Hole
NCT03677869
Conditions: Vitreomacular Traction (VMT); and Full-thickness Macular Holes (MH)
Intervention: Device: Intraocular gas (C3F8)
Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI)
Recruiting
National Cardiogenic Shock Initiative
NCT03677180
Conditions: Cardiogenic Shock; Acute Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI; Heart Attack
Intervention:
Sponsors: Henry Ford Health System; Abiomed Inc.; Chiesi Farmaceutici S.p.A.
Recruiting
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
NCT03654768
Condition: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Nilotinib; Drug: Ruxolitinib Phosphate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Condition: Relapsing Multiple Sclerosis
Interventions: Biological: Ofatumumab; Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap); Biological: 13-valent pneumococcal conjugate vaccine (13-PCV); Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV); Biological: Seasonal Quadrivalent influenza vaccine; Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
Sponsor: Novartis Pharmaceuticals
Recruiting
Effects of Pneumatic Vitreolysis on Vitreomacular Traction
NCT03647267
Condition: Vitreomacular Traction
Interventions: Device: Pneumatic Vitreolysis (C3F8 injection); Other: Observation
Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI)
Recruiting
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302
NCT03635996
Condition: Paroxysmal Supraventricular Tachycardia
Intervention: Drug: Etripamil NS 70 mg
Sponsors: Milestone Pharmaceuticals Inc.; Medpace, Inc.
Recruiting
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
NCT03617367
Condition: Cervical Dystonia
Intervention: Biological: daxibotulinumtoxinA for injection
Sponsors: Revance Therapeutics, Inc.; Syneos Health
Recruiting
Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
NCT03608397
Condition: Cervical Dystonia
Interventions: Biological: DaxibotulinumtoxinA for injection; Biological: Placebo
Sponsors: Revance Therapeutics, Inc.; Syneos Health
Recruiting
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
NCT03607838
Condition: Lumbar Disc Herniation
Interventions: Drug: SI-6603; Drug: Sham injection
Sponsor: Seikagaku Corporation
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03598790
Conditions: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis
Intervention: Drug: Bimekizumab
Sponsor: UCB Biopharma S.P.R.L.
Recruiting
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03598257
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: Olaparib; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Comparison of the Effects of Two Spinal Cord Stimulation (SCS) Therapies on Subject Reported Pain (BENEFIT-02)
NCT03594266
Conditions: Chronic Low Back Pain; Chronic Leg Pain
Interventions: Device: Therapy A Spinal Cord Stimulation Parameter Set; Device: Therapy B Spinal Cord Stimulation Parameter Set
Sponsor: Biotronik, Inc.
Recruiting
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
NCT03587805
Condition: Atopic Dermatitis
Intervention: Drug: Tralokinumab
Sponsor: LEO Pharma
Recruiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Condition: Malignant Neoplasm
Interventions: Drug: Palonosetron Hydrochloride; Drug: Ondansetron Hydrochloride; Drug: Dexamethasone; Drug: Fosaprepitant Dimeglumine; Drug: Olanzapine; Other: Placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Conditions: Overweight; Obesity
Interventions: Drug: Semaglutide; Drug: Placebo (semaglutide)
Sponsor: Novo Nordisk A/S
Recruiting
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NCT03488693
Condition: Breast Cancer
Interventions: Radiation: Radiation; Other: No Radiation
Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group
Recruiting
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
Condition: Acute Coronary Syndrome
Interventions: Biological: Apolipoprotein A-I [human] (apoA-I); Other: Placebo
Sponsor: CSL Behring
Recruiting
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
NCT03464019
Condition: Paroxysmal Supraventricular Tachycardia
Interventions: Drug: Etripamil; Drug: Placebo; Device: Aptar Pharma Nasal Spray
Sponsors: Milestone Pharmaceuticals Inc.; Medpace, Inc.
Recruiting
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
NCT03409107
Condition: Anaemia
Interventions: Drug: Daprodustat (GSK1278863); Drug: Placebo; Drug: Iron therapy
Sponsor: GlaxoSmithKline
Recruiting
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
NCT03373045
Condition: Asthma
Intervention:
Sponsors: AstraZeneca; Parexel; MedImmune LLC
Recruiting
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
NCT03372161
Condition: Lumbosacral Radicular Pain
Interventions: Drug: SP-102; Drug: Placebo
Sponsors: Semnur Pharmaceuticals, Inc.; Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.
Recruiting
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
NCT03371719
Conditions: PSA Progression; Stage III Prostate Adenocarcinoma; Stage IV Prostate Adenocarcinoma
Interventions: Drug: Apalutamide; Radiation: External Beam Radiation Therapy; Other: Placebo
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702
Condition: Stage II Prostate Adenocarcinoma
Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954
Conditions: Myelodysplastic Syndrome; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine; Drug: Pevonedistat
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258554
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma of Unknown Primary; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biological: Cetuximab; Biological: Durvalumab; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group; NRG Oncology
Recruiting
MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
NCT03217266
Condition: Soft Tissue Sarcoma
Interventions: Drug: MDM2 Inhibitor AMG-232; Radiation: Radiation Therapy
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
NCT03199885
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Biological: Trastuzumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Conditions: Grade II Meningioma; Intracranial Meningioma
Interventions: Other: Clinical Observation; Radiation: Radiation Therapy
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771
Conditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT); Drug: Docetaxel; Drug: Gemcitabine; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Pemetrexed Disodium; Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: Erlotinib Hydrochloride; Drug: Pembrolizumab
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886
Conditions: Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Interventions: Drug: Bicalutamide; Drug: Docetaxel; Radiation: External Beam Radiation Therapy; Drug: Flutamide; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Drug: Leuprolide Acetate; Drug: Nilutamide
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
NCT03044249
Conditions: Psychosis; Dementia; Aggression; Agitation; Alzheimer Dementia
Interventions: Drug: MP-101; Drug: Placebo
Sponsor: Mediti Pharma Inc.
Recruiting
Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
NCT03033576
Conditions: Advanced Melanoma; Melanoma of Unknown Primary; Mucosal Melanoma; Refractory Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
NCT03028350
Condition: Asthma, Aspirin-Induced
Interventions: Drug: Ifetroban Oral Capsule; Drug: Placebo Oral Capsule
Sponsor: Cumberland Pharmaceuticals
Recruiting
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
NCT02928497
Condition: Stroke
Interventions: Device: WATCHMAN LAAC Device Implant; Drug: Single Antiplatelet Therapy or No Therapy (Control)
Sponsor: Boston Scientific Corporation
Recruiting
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
NCT02923726
Condition: Sudden Cardiac Death
Interventions: Device: Arm 1 (ATP+Shock); Device: Arm 2 (shock only)
Sponsors: Boston Scientific Corporation; ICON plc
Recruiting
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
NCT02728596
Conditions: Febrile Neutropenia; Stage 0 Breast Cancer; Stage 0 Colorectal Cancer; Stage 0 Non-Small Cell Lung Cancer; Stage I Colorectal Cancer; Stage IA Breast Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Breast Cancer; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Breast Cancer; Stage IIA Colorectal Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Breast Cancer; Stage IIB Colorectal Cancer; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIC Colorectal Cancer; Stage IIIA Breast Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IIIC Colorectal Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer
Interventions: Other: Preventive Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Patient-Centered Outcomes Research Institute
Recruiting
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
NCT02635009
Conditions: Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Cognitive Assessment; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Capecitabine in Metastatic Breast and GI Cancers
NCT02595320
Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Drug: Capecitabine
Sponsor: Qamar Khan
Recruiting
aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation
NCT02513797
Condition: Atrial Fibrillation
Interventions: Device: LARIAT + PVI; Device: Pulmonary Vein Isolation
Sponsor: AtriCure, Inc.
Recruiting
Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT02507687
Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: Bimatoprost SR; Drug: Sham Bimatoprost SR; Procedure: Selective Laser Trabeculoplasty; Procedure: Sham Selective Laser Trabeculoplasty
Sponsor: Allergan
Recruiting
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
NCT02466971
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7; Vaginal Adenocarcinoma; Vaginal Adenosquamous Carcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Drug: Triapine
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: photon beam radiation therapy; Radiation: proton beam radiation therapy; Drug: temozolomide; Other: laboratory biomarker analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Dimethyl Fumarate (DMF) Observational Study
NCT02047097
Condition: Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
Sponsor: Biogen
Recruiting
Integrated Cancer Repository for Cancer Research
NCT02012699
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control
Intervention:
Sponsor: University of Nebraska
Recruiting
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NCT01872975
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI
Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
NCT04178967
Condition: Atopic Dermatitis
Interventions: Biological: Lebrikizumab; Other: Placebo
Sponsor: Dermira, Inc.
Recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488
Conditions: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Dacarbazine; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Biological: Filgrastim; Biological: Nivolumab; Biological: Pegfilgrastim; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Vinblastine; Drug: Vinblastine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
NCT03769090
Condition: Asthma
Interventions: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg; Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg; Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
Sponsor: Bond Avillion 2 Development LP
Recruiting
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
NCT03627767
Conditions: Dermatitis; Dermatitis, Atopic; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases
Interventions: Drug: PF-04965842 100 mg; Drug: PF-04965842 200 mg; Drug: Placebo
Sponsor: Pfizer
Recruiting
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
NCT03580369
Condition: Chronic Spontaneous Urticaria
Interventions: Biological: Ligelizumab; Biological: Omalizumab; Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318
Condition: Atopic Dermatitis
Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib; Drug: Topical corticosteroids (TCS)
Sponsor: AbbVie
Recruiting
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
NCT03428646
Condition: Dermatitis, Atopic
Intervention: Drug: Dupilumab
Sponsors: Regeneron Pharmaceuticals; Sanofi
Recruiting
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822
Condition: Dermatitis, Atopic
Interventions: Drug: PF-04965842 100 mg; Drug: PF-04965842 200 mg; Drug: Placebo
Sponsor: Pfizer
Recruiting
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
NCT03052517
Condition: Asthma
Interventions: Drug: QAW039 Dose 1; Drug: QAW039 Dose 2; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
NCT01442194
Condition: Multiple Sclerosis
Interventions: Drug: other disease-modifying therapy; Drug: Fingolimod
Sponsor: Novartis Pharmaceuticals
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now